Health news, medical discoveries and wellness tips
AI analysis of 400,000 Reddit posts identified potential overlooked symptoms associated with GLP-1 drugs like Ozempic, including menstrual changes and temperature fluctuations. Researchers caution these are signals, not proof of causation.
New Phase 2 data from the DeLLphi-309 study suggest tarlatamab can be effectively administered at extended intervals (every three or four weeks) in relapsed SCLC patients, maintaining comparable efficacy and safety to the standard every-two-week regimen. This offers greater treatment flexibility.
A Phase 1b trial of subcutaneous tarlatamab for extensive-stage small cell lung cancer (ES-SCLC) demonstrated a favorable safety profile with low rates of severe adverse events, including cytokine release syndrome (CRS). The new administration route showed comparable drug exposure to the intravenous form and preliminary antitumor activity, supporting further development.
A new study reveals a startling connection between regular eyelash extension use and a high prevalence of Demodex mites. Researchers found mites in 96% of participants who frequently used extensions, raising concerns about eye health and hygiene.
Cancer has become the leading health threat for 9/11 survivors, with aid for treatment tripling in five years. Nearly half of enrolled survivors now face cancer, a significant rise attributed to toxic dust exposure.
Concerns mount over the CDC's reliability as it navigates measles deaths amid falling vaccination rates and resurgent diseases. Political interference fears surface.
Dr. Rupa Narra, a US pediatrician, describes the harrowing reality of treating Ebola's youngest victims in the DRC. With no approved antivirals for the Bundibugyo strain and a fragile healthcare system exacerbated by conflict, children face a grim prognosis, with a disproportionately high death rate.
Novartis's experimental heart drug pelacarsen, widely anticipated to reduce heart attacks and strokes, has failed a large seven-year clinical trial. Despite significantly lowering lipoprotein(a) levels, the drug showed no benefit over placebo in preventing major cardiovascular events or deaths, disappointing cardiologists and raising questions about the direct causal link between Lp(a) and heart disease.
Leipzig University researchers identified a compound, AP503, that activates the GPR133 receptor, significantly boosting bone formation and reducing loss in mice. This discovery holds promise for new osteoporosis treatments and combating age-related decline.